- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05503953
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
August 16, 2022 updated by: Ahn-Gook Pharmaceuticals Co.,Ltd
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
306
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Hypertension patient who satisfied below condition at Visit 1.
patient who takes antihypertensive drug
- 140mmHg <= MSSBP < 200mmHg
- 130mmHg <= MSSBP < 200mmHg at or before visit 1(In high-risk patients)
patient who doesn't take antihypertensive drug
- 160mmHg <= MSSBP < 200mmHg
Hypertension patient who satisfied below condition at Visit 2.
- 140mmHg <= MSSBP < 200mmHg at Visit 2
- 130mmHg <= MSSBP < 200mmHg at or before Visit 1(In high-risk patients)
Exclusion Criteria:
- Patient who have received 4 or more antihypertensive drug
- Patient with 20mmHg>= of difference in MSSBP or 10mmHg>= of difference in MSDBP between 2 times of BP measuring at Visit 1
- Patient with MSDBP >= 120mmHg at Visit 1 or 2
- Patient with secondary hypertension(including past medical history)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AGSAVI
|
Uptitation
|
ACTIVE_COMPARATOR: AGLS
|
Uptitration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of MSSBP(Mean Sitting Systolic Blood Pressure)
Time Frame: From Baseline(Visit 2) to Visit 5(For 10 weeks)
|
Change of MSSBP(Mean Sitting Systolic Blood Pressure) From Baseline to Visit 5(For 10 weeks)
|
From Baseline(Visit 2) to Visit 5(For 10 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 5, 2022
Primary Completion (ANTICIPATED)
February 29, 2024
Study Completion (ANTICIPATED)
July 31, 2024
Study Registration Dates
First Submitted
August 15, 2022
First Submitted That Met QC Criteria
August 15, 2022
First Posted (ACTUAL)
August 17, 2022
Study Record Updates
Last Update Posted (ACTUAL)
August 18, 2022
Last Update Submitted That Met QC Criteria
August 16, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG-1705_P3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Hypertension
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Addpharma Inc.Completed
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
BayerCompletedHypertension, EssentialGermany
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Instituto de Cardiologia do Rio Grande do SulRecruitingHypertension | Hypertension,EssentialBrazil
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLCNot yet recruitingHypertension | Hypertension,Essential
Clinical Trials on AGSAVI
-
Ahn-Gook Pharmaceuticals Co.,LtdUnknown